查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014510

勃起功能障礙治療市場：2026-2032年全球市場預測（依治療時間、劑量、病患年齡層和通路分類）

Erectile Dysfunction Drugs Market by Treatment Duration, Dosage Strength, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，勃起功能障礙治療市場價值將達到 27.5 億美元，到 2026 年將成長至 29.3 億美元，到 2032 年將達到 46.7 億美元，複合年成長率為 7.82%。

主要市場統計數據
基準年 2025 27.5億美元
預計年份：2026年 29.3億美元
預測年份 2032 46.7億美元
複合年成長率 (%) 7.82%

勃起功能障礙的治療處於臨床實踐、不斷變化的患者期​​望和支付方趨勢等諸多複雜因素的交匯點。近年來，藥理學、數位醫療整合以及病人參與模式的進步，共同重塑了臨床醫生和生物技術公司開發和商業化治療方法的方式。同時，旨在消除社會歧視和廣泛宣傳的宣傳活動鼓勵更多患者尋求治療，而遠端醫療和線上藥局管道則為診斷和啟動治療提供了新的途徑。

在此背景下，相關人員需要整合臨床證據、監管趨勢、不斷變化的管道以及患者行為的可操作性洞察。臨床醫師在建議治療方法時，越來越重視療效、耐受性和便利性之間的平衡。同時，品牌藥和學名藥都在影響處方模式，製藥開發商必須應對日益激烈的競爭環境。支付方和醫療保健系統正在調整福利框架和利用管理，製造商需要透過長期安全性和生活品質數據來證明其價值，而不僅僅是緩解症狀。

本執行摘要總結了治療方法、通路、管理注意事項和人口統計需求促進因素等方面的關鍵趨勢和決策見解。其旨在幫助產業領導者、臨床專案經理和商業負責人了解影響勃起功能障礙治療當前及近期發展格局的關鍵促進因素，為後續策略考量提供簡潔而全面的基礎。

藥物創新、數位化醫療服務和支付方審查如何融合，重新定義勃起功能障礙治療的療效和病人就醫途徑。

勃起功能障礙的治療格局正在經歷一場變革，這主要得益於藥物創新、數位化醫療服務以及患者期望的不斷提高。新型製劑和給藥系統的出現，以及對藥物耐受性和起效時間的重新關注，正在拓展泌尿系統和基層醫療領域關於治療方案的討論範圍。同時，數位化醫療平台和遠端醫療正在降低患者就診和處方箋的門檻，縮短許多患者的治療等待時間。

本研究評估了 2025 年定價環境對治療勃起功能障礙藥物的持續性、定價和患者獲取途徑的運作、採購和分銷影響。

2025年新關稅措施和貿易政策的訂定，為整個醫藥價值鏈上的製造商、經銷商和藥房網路帶來了一系列營運和供應鏈方面的挑戰。關稅結構的變化正在影響活性成分和製劑的籌資策略，促使一些公司尋求供應商多元化、重新評估庫存策略並重新評估區域製造地。為此，多家機構正在加快緊急時應對計畫，以維持供應的連續性並保護利潤率。

針對銷售模式、治療持續時間、通路、劑型和患者年齡層等細分市場的特定洞察，推動有針對性的商業化。

細分市場的趨勢揭示了獨特的機會和挑戰，這些機會和挑戰因產品模式、療程、通路、劑型和患者年齡層而異。考慮到銷售模式的差異，品牌藥繼續透過附加價值服務、臨床證據包和有針對性的患者支援計劃來追求差異化，而學名藥在價格和可及性方面展開競爭，這給整個處方和報銷管道帶來了壓力。在療程方面，長期療法面臨著用藥依從性和安全性監測方面的挑戰，這推動了對病人參與工具和治療結果追蹤的需求。另一方面，短期療法則優先考慮快速起效、便利性和最大限度地減輕患者負擔。

美洲、歐洲、中東和非洲以及亞太地區在准入、監管重點和病患行為方面的區域差異，正在影響著針對每個地區量身定做的市場策略。

區域趨勢顯示，臨床實務模式、監管重點和患者行為有顯著差異，進而影響治療方法和商業策略。在美洲，成熟的醫療保健生態系統整合了高數位化普及率以及完善的專科藥房和零售藥房網路，創造出一種以遠端醫療、患者直接參與和與保險公司談判為核心的患者獲取和留存環境。在美洲，整合式醫療路徑和價值論證往往是藥物推廣的優先考慮因素，這進一步凸顯了真實世界數據和健康結果數據的重要性。

領先的製藥和產品公司如何將臨床差異化、全通路互動和供應鏈韌性結合起來，以加強其治療定位？

治療勃起功能障礙領域的主要企業正透過臨床差異化、生命週期管理和通路最佳化來保持競爭優勢。一些企業致力於透過整合支援計畫、數位化用藥依從性工具以及將臨床護理與便利的配藥方式相結合的夥伴關係來改善病患體驗。另一些企業則強調製劑創新和新型給藥系統，旨在逐步提高起效速度、耐受性或易用性，從而建立能夠引起處方醫生共鳴的獨特臨床案例。

為了維持治療和商業性的成功，經營團隊面臨的策略挑戰是協調證據產生、全通路存取、供應彈性和以人口統計為中心的定位。

行業領導者應優先考慮一系列切實可行的步驟，協調臨床開發、商業性執行和患者可及性的目標，以最大限度地提高治療效果和組織韌性。首先，將真實世界證據的創建和患者報告結果的收集納入核准後項目，以支持與支付方的磋商，並展現超越症狀控制的長期價值。這些證據將有助於建立更具說服力的價值提案，並有助於在不同的報銷環境下獲得有利的報銷條款。

概述調查方法，詳細介紹文獻整合、相關人員訪談和交叉細分分析，以確保獲得穩健且可操作的治療結果。

本研究採用綜合分析方法，結合嚴謹的二手資料分析、相關人員訪談和結構化證據審查，旨在為臨床、商業和營運決策者提供切實可行的見解。二手資料分析涵蓋了同行評審的臨床文獻、監管機構通告、已發布的治療指南以及公開的政策文件，從而構建了科學和監管背景的基礎。這些資訊來源用於梳理關鍵治療場景中的治療模式、安全考量以及基於指南的實踐現狀。

結論強調，以實證臨床故事、管道柔軟性和細分為重點的商業化對於實現永續的患者療效和商業性成功至關重要。

當前勃起功能障礙的治療格局呈現出患者參與方式日益多元化、對便利性和隱私性期望不斷提高以及品牌藥和學名藥之間商業性競爭日益激烈的特徵。這些趨勢凸顯了整合策略的必要性，該策略應結合臨床差異化、以患者為中心的就醫管道以及穩健的營運模式。在可操作的臨床終點和患者報告結果方面建立可靠的證據，對於確保獲得有利的報銷條款和維持處方醫生的信心至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療時間分類的勃起功能障礙治療市場

  • 長期
  • 短期

第9章：按劑量分類的勃起功能障礙治療藥物市場

  • 100 mg
  • 25 mg
  • 50 mg

第10章：依患者年齡層分類的勃起功能障礙治療市場

  • 40-60歲
  • 60歲或以上
  • 40歲以下

第11章 勃起功能障礙治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 勃起功能障礙治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 勃起功能障礙治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 勃起功能障礙治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國勃起功能障礙治療市場

第16章：中國治療勃起功能障礙的市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Apricus Biosciences, Inc.
  • Aurobindo Pharma Limited
  • Auxilium Pharmaceuticals, Inc.
  • Bayer AG
  • Cipla Limited
  • Dong-A Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Futura Medical plc
  • GlaxoSmithKline plc
  • Lupin Limited
  • Petros Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SK Chemicals Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vivus Inc.
Product Code: MRR-4348D129FAF4

The Erectile Dysfunction Drugs Market was valued at USD 2.75 billion in 2025 and is projected to grow to USD 2.93 billion in 2026, with a CAGR of 7.82%, reaching USD 4.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.75 billion
Estimated Year [2026] USD 2.93 billion
Forecast Year [2032] USD 4.67 billion
CAGR (%) 7.82%

Erectile dysfunction therapeutics occupy a complex intersection of clinical practice, evolving patient expectations, and shifting payer dynamics. Recent years have seen advances in pharmacology, digital health integration, and patient engagement models that collectively reshape how clinicians and biotech companies approach treatment development and commercialization. Simultaneously, stigma reduction efforts and broader awareness campaigns have driven more patients to seek care, while telemedicine and online pharmacy channels have offered new pathways for diagnosis and treatment initiation.

Against this backdrop, stakeholders require actionable intelligence that synthesizes clinical evidence, regulatory trends, distribution channel evolution, and patient behavior. Clinicians increasingly balance efficacy, tolerability, and convenience when recommending therapies, while pharmaceutical developers must navigate a more crowded competitive landscape with both branded and generic options influencing prescribing patterns. Payers and health systems are adjusting coverage frameworks and utilization management, prompting manufacturers to demonstrate value beyond symptomatic relief through long-term safety and quality-of-life data.

This executive summary condenses critical thematic developments and decision-relevant insights across therapy modalities, distribution pathways, dosing considerations, and demographic demand drivers. It aims to orient industry leaders, clinical program managers, and commercial strategists to the principal forces shaping the erectile dysfunction therapeutic environment today and near term, providing a concise yet comprehensive foundation for subsequent strategic deliberations.

How pharmacologic innovation, digital care delivery, and payer scrutiny are converging to redefine therapeutic success and patient access in erectile dysfunction care

The erectile dysfunction therapeutic landscape is undergoing transformative shifts driven by innovation in pharmacology, digital care delivery, and evolving patient expectations. Novel formulations and delivery systems, alongside renewed emphasis on tolerability and onset of action, have broadened therapeutic conversations within urology and primary care. Meanwhile, digital health platforms and telemedicine have reduced friction in obtaining consultation and prescriptions, accelerating time to treatment initiation for many patients.

Concurrently, competitive dynamics are intensifying as established branded therapies face generic entrants and as companies explore lifecycle strategies that emphasize convenience, proprietary formulations, and patient support services. Payers are responding by refining coverage criteria and prior authorization frameworks, which has elevated the importance of robust real-world evidence and health-economic arguments in commercial planning. These interconnected trends have pushed manufacturers to align clinical development with pragmatic endpoints, patient-reported outcomes, and adherence-support initiatives.

Regulatory and reimbursement environments are also adapting, with agencies showing interest in comparative effectiveness data and post-marketing safety surveillance for sexual health products. This, coupled with a more informed patient population seeking discreet, convenient, and effective solutions, reinforces the need for integrated approaches that combine clinical differentiation with superior patient experiences. Ultimately, the confluence of pharmacological innovation, digital access, and payer scrutiny is redefining success metrics in the therapeutic area and prompting stakeholders to adopt more agile, evidence-driven strategies.

Assessing the operational, sourcing, and distribution implications of the 2025 tariff environment on continuity, pricing, and patient access for erectile dysfunction therapeutics

The introduction of new tariff measures and trade policies in 2025 has introduced a set of operational and supply-chain considerations for manufacturers, distributors, and pharmacy networks across the pharmaceutical value chain. Changes in tariff structures have influenced sourcing strategies for active pharmaceutical ingredients and finished dosage forms, encouraging some companies to re-evaluate supplier diversification, inventory strategies, and regional manufacturing footprints. In response, several organizations have accelerated nearshoring discussions and contingency planning to maintain supply continuity and protect margin profiles.

At the distribution level, tariff-related cost pressures have led stakeholders to reassess pricing transparency and contractual terms with wholesalers and pharmacy partners. These pressures have also prompted more rigorous cost-to-serve analyses by manufacturers, with an emphasis on optimizing logistics networks and leveraging bulk procurement where clinically feasible. In parallel, digital channels such as online pharmacies have become focal points for preserving patient access, given their capacity to mitigate certain distribution frictions and meet patient preferences for discreet, convenient fulfillment.

Beyond operational adjustments, the cumulative tariff impacts of 2025 have prompted renewed dialogue between commercial teams and market access functions to ensure product affordability and adherence to local reimbursement policies. Manufacturers pursuing global strategies have increased coordination between regulatory, supply-chain, and commercial teams to anticipate cross-border implications and to design pricing strategies that preserve therapeutic accessibility. As a result, supply resilience, flexible sourcing, and coordinated stakeholder engagement have emerged as central priorities for entities seeking to manage tariff-related volatility while sustaining patient access to erectile dysfunction therapies.

Segment-driven insights across sales models, treatment durations, distribution channels, dosage strengths, and patient age cohorts to guide targeted commercialization

Segment-specific dynamics reveal differentiated opportunities and challenges that vary by product model, treatment duration, distribution pathway, dosage strength, and patient age cohort. When considering sales model distinctions, branded products continue to pursue differentiation through value-added services, clinical evidence packages, and targeted patient support programs, while generic alternatives compete on price and accessibility, exerting pressure across prescribing and reimbursement channels. In the domain of treatment duration, long-term regimens face adherence and safety monitoring considerations that drive demand for patient engagement tools and outcome tracking, whereas short-term therapies emphasize rapid onset, convenience, and minimal interaction burden.

Distribution channel segmentation highlights the growing significance of online pharmacy fulfillment as a complement to traditional hospital pharmacy and retail pharmacy networks; digital channels offer convenience and confidentiality that resonate strongly with patients seeking discreet treatment, while hospital pharmacies remain critical for integrated care pathways where comorbidities and specialist oversight are paramount. Examination of dosage strength preferences indicates that varying needs across clinical presentations and comorbidity profiles make 25 mg, 50 mg, and 100 mg options strategically important for prescribers who tailor dosing to efficacy and tolerability considerations. Age-based segmentation underscores distinct motivational and clinical factors: individuals under 40 often prioritize convenience and minimal side effects, patients aged 40-60 balance efficacy with lifestyle impact and partner considerations, and those 60 and older typically emphasize safety, comorbidity management, and interactions with concomitant medications.

Integrating these segmentation lenses allows stakeholders to craft differentiated product positioning, commercial tactics, and patient support mechanisms that align with prescriber decision-making and patient preferences. For example, combining branded value propositions with robust telehealth-enabled adherence services may enhance long-term therapy outcomes, while ensuring competitive pricing and streamlined access in online pharmacy channels can expand reach for short-duration interventions. Taken together, segmentation-informed strategies are essential to optimize uptake, adherence, and therapeutic success across diverse patient cohorts and distribution environments.

Regional differentiation in access, regulatory emphasis, and patient behavior across the Americas, Europe Middle East & Africa, and Asia-Pacific influencing tailored market approaches

Regional dynamics present notable variations in clinical practice patterns, regulatory emphasis, and patient behavior that influence therapeutic approaches and commercial tactics. In the Americas, a mature healthcare ecosystem combines high digital adoption with established specialty and retail pharmacy networks, creating an environment where telemedicine, direct-to-patient engagement, and payer negotiation play central roles in patient acquisition and retention. The Americas often prioritize integrated care pathways and value demonstration for formulary positioning, which amplifies the importance of real-world evidence and health outcomes data.

The Europe, Middle East & Africa region exhibits considerable heterogeneity in regulatory frameworks, reimbursement systems, and healthcare access. Western European markets tend to emphasize comparative effectiveness and cost-effectiveness assessments, whereas several Middle Eastern and African markets prioritize access expansion and supply reliability. Cross-border procurement dynamics and varying distribution infrastructures require tailored market entry strategies, with localized evidence generation and partnership models that address regional payer expectations and logistical constraints.

Asia-Pacific encompasses a broad spectrum of healthcare maturation levels and cultural attitudes toward sexual health, with rapid digital adoption in many urban centers facilitating telehealth and e-pharmacy solutions. Countries within the region vary in regulatory pathways and pricing mechanisms, necessitating a nuanced approach to commercialization that considers local prescribing behaviors, reimbursement levers, and the role of over-the-counter availability in some jurisdictions. Across all regions, aligning clinical messaging with cultural sensitivities, regulatory requirements, and distribution realities is essential to achieve both clinical impact and sustainable commercial performance.

How leading pharmaceutical and product companies are combining clinical differentiation, omnichannel engagement, and supply-chain resilience to strengthen therapeutic positioning

Leading companies within the erectile dysfunction therapeutic space are pursuing a combination of clinical differentiation, lifecycle management, and channel optimization to sustain competitive positioning. Several firms focus on enhancing the patient journey through integrated support programs, digital adherence tools, and partnerships that bridge clinical care with convenient fulfillment options. Others emphasize formulation innovations or novel delivery systems that seek incremental improvements in onset of action, tolerability, or ease of use, thereby creating distinct clinical narratives that resonate with prescribers.

Commercially, companies are investing in omnichannel engagement strategies that align with patient preferences for discrete, fast access while maintaining strong relationships with specialist and primary care prescribers. Strategic alliances with telehealth providers and licensed online pharmacies have become increasingly important as firms aim to capture demand from digitally enabled patients. At the same time, some organizations prioritize supply-chain resilience and regional manufacturing flexibility to mitigate trade policy disruptions and ensure consistent availability across diverse distribution networks.

On the evidence front, there is a discernible emphasis on collecting pragmatic clinical data and patient-reported outcomes to substantiate claims around quality of life and long-term safety. Companies that combine robust clinical portfolios with scalable patient support and flexible channel strategies are positioned to respond swiftly to evolving payer requirements and shifting patient expectations, thereby strengthening their ability to sustain uptake and adherence across multiple treatment settings.

Strategic imperatives for executives to align evidence generation, omnichannel access, supply resilience, and demographic-focused positioning to sustain therapeutic and commercial success

Industry leaders should prioritize a set of actionable steps that align clinical development, commercial execution, and patient access objectives to maximize therapeutic impact and organizational resilience. First, integrate real-world evidence generation and patient-reported outcome collection into post-approval programs to support payer discussions and to demonstrate long-term value beyond symptom control. This evidence base will underpin more persuasive value propositions and help secure favorable coverage terms in diverse reimbursement environments.

Second, invest in omnichannel distribution and patient engagement strategies that combine traditional pharmacy relationships with telehealth partnerships and online pharmacy fulfillment. A coordinated approach ensures patients can access therapies discreetly and conveniently while maintaining clinician oversight where necessary. Third, diversify sourcing and manufacturing strategies to reduce exposure to tariff-driven disruptions and to maintain supply continuity. Nearshoring, multi-sourcing, and strategic inventory buffers can reduce operational risk and preserve commercial momentum.

Fourth, tailor product positioning and dosing options to demographic and clinical segments, ensuring that messaging resonates with under 40, 40-60, and 60+ patient cohorts and that prescribers have clear guidance on dose selection across 25 mg, 50 mg, and 100 mg options. Finally, cultivate collaborative relationships with payers and health systems by aligning clinical endpoints with health-economic priorities and by offering programs that support adherence and appropriate utilization. Executing on these priorities will require cross-functional alignment among clinical, regulatory, commercial, and supply-chain teams to translate insights into measurable outcomes.

Methodological overview detailing literature synthesis, stakeholder interviews, and cross-segmentation analysis to ensure robust and actionable therapeutic insights

This research synthesis combines rigorous secondary-source analysis, stakeholder interviews, and structured evidence review to produce actionable insights relevant to clinical, commercial, and operational decision makers. Secondary analysis encompassed peer-reviewed clinical literature, regulatory communications, published treatment guidelines, and publicly available policy documents to establish a foundation of scientific and regulatory context. These sources were used to map treatment paradigms, safety considerations, and guideline-directed practice across major therapeutic settings.

To complement the literature review, qualitative interviews were conducted with a diverse set of stakeholders including clinicians, pharmacy leaders, payers, and digital health partners to capture frontline perspectives on prescribing behavior, patient engagement, and distribution channel dynamics. Interview inputs were triangulated with observational data on channel growth patterns and with publicly reported corporate initiatives to ensure a balanced interpretation of strategic priorities and operational constraints.

Analytical methods included cross-segmentation synthesis to examine interactions between sales models, treatment durations, distribution channels, dosage strengths, and patient age cohorts, as well as scenario-based assessment of supply-chain impacts from recent tariff changes. Throughout the research process, data integrity checks and source triangulation were applied to minimize bias and to ensure that conclusions reflect convergent signals across evidence streams. The methodological approach emphasizes transparency, replicability, and practical relevance for stakeholders seeking to apply the insights to strategic planning and operational execution.

Conclusion emphasizing the need for evidence-driven clinical narratives, channel flexibility, and segmentation-focused commercialization to achieve sustained patient and commercial outcomes

The current therapeutic landscape for erectile dysfunction is characterized by expanding patient engagement avenues, heightened expectations for convenience and discretion, and intensifying commercial competition between branded and generic options. These dynamics underscore the need for integrated strategies that marry clinical differentiation with patient-centric access pathways and resilient operational models. Robust evidence generation, across both pragmatic clinical endpoints and patient-reported outcomes, will be increasingly important to secure favorable reimbursement outcomes and to sustain prescriber confidence.

Moreover, segmentation-aware commercialization-attuned to differences by sales model, treatment duration, channel preference, dosage strength, and age cohort-enables more precise targeting and higher likelihood of therapeutic adherence and satisfaction. Regional nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific further necessitate tailored approaches that respect local regulatory expectations, cultural attitudes, and distribution realities. Finally, operational imperatives such as diversified sourcing and digital channel partnerships will be central to maintaining access and managing cost pressures introduced by trade dynamics.

In sum, organizations that blend evidence-based clinical narratives, flexible distribution architectures, and customer-centric engagement models will be best positioned to navigate the evolving environment and to deliver sustained patient and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Drugs Market, by Treatment Duration

  • 8.1. Long-Term
  • 8.2. Short-Term

9. Erectile Dysfunction Drugs Market, by Dosage Strength

  • 9.1. 100 Mg
  • 9.2. 25 Mg
  • 9.3. 50 Mg

10. Erectile Dysfunction Drugs Market, by Patient Age Group

  • 10.1. 40-60 Years
  • 10.2. 60+ Years
  • 10.3. Under 40 Years

11. Erectile Dysfunction Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Erectile Dysfunction Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Erectile Dysfunction Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Erectile Dysfunction Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Erectile Dysfunction Drugs Market

16. China Erectile Dysfunction Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Apricus Biosciences, Inc.
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Auxilium Pharmaceuticals, Inc.
  • 17.8. Bayer AG
  • 17.9. Cipla Limited
  • 17.10. Dong-A Pharmaceutical Co., Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. Endo International plc
  • 17.13. Futura Medical plc
  • 17.14. GlaxoSmithKline plc
  • 17.15. Lupin Limited
  • 17.16. Petros Pharmaceuticals Inc.
  • 17.17. Pfizer Inc.
  • 17.18. Sanofi S.A.
  • 17.19. SK Chemicals Co., Ltd.
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Viatris Inc.
  • 17.23. Vivus Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 88. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GCC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 103. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 104. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. G7 ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 108. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 109. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. NATO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)